188 related articles for article (PubMed ID: 36505399)
21. [Application of Immune Checkpoint Inhibitors in EGFR Mutant
Advanced Non-small Cell Lung Cancer].
Zheng Y; Jiang W; Li J; Dai L; Chen D; Li Y; Huang L; Wang M
Zhongguo Fei Ai Za Zhi; 2022 Sep; 25(9):671-677. PubMed ID: 36172732
[TBL] [Abstract][Full Text] [Related]
22. A non-small cell lung cancer (NSCLC) patient harboring a rare epidermal growth factor receptor (EGFR) L858R/V843I mutation complex benefited from osimertinib: a case report.
Zhou Y; Qi X; Wang Y; Dong H; Zhuang L
Ann Palliat Med; 2022 Mar; 11(3):1121-1125. PubMed ID: 35365042
[TBL] [Abstract][Full Text] [Related]
23. Various Subtypes of EGFR Mutations in Patients With NSCLC Define Genetic, Immunologic Diversity and Possess Different Prognostic Biomarkers.
Lei Y; Wang K; Liu Y; Wang X; Xiang X; Ning X; Ding W; Duan J; Li D; Zhao W; Li Y; Zhang F; Luo X; Shi Y; Wang Y; Huang D; Bai Y; Zhang H
Front Immunol; 2022; 13():811601. PubMed ID: 35265073
[TBL] [Abstract][Full Text] [Related]
24. PD-L1 expression and T cells infiltration in patients with uncommon EGFR-mutant non-small cell lung cancer and the response to immunotherapy.
Chen K; Cheng G; Zhang F; Zhu G; Xu Y; Yu X; Huang Z; Fan Y
Lung Cancer; 2020 Apr; 142():98-105. PubMed ID: 32120230
[TBL] [Abstract][Full Text] [Related]
25. Epidermal growth factor receptor tyrosine kinase inhibitor remodels tumor microenvironment by upregulating LAG-3 in advanced non-small-cell lung cancer.
Zhou J; Yu X; Hou L; Zhao J; Zhou F; Chu X; Wu Y; Zhou C; Su C
Lung Cancer; 2021 Mar; 153():143-149. PubMed ID: 33508527
[TBL] [Abstract][Full Text] [Related]
26. Radiomics for the prediction of EGFR mutation subtypes in non-small cell lung cancer.
Li S; Ding C; Zhang H; Song J; Wu L
Med Phys; 2019 Oct; 46(10):4545-4552. PubMed ID: 31376283
[TBL] [Abstract][Full Text] [Related]
27. Genomic analysis of 63,220 tumors reveals insights into tumor uniqueness and targeted cancer immunotherapy strategies.
Hartmaier RJ; Charo J; Fabrizio D; Goldberg ME; Albacker LA; Pao W; Chmielecki J
Genome Med; 2017 Feb; 9(1):16. PubMed ID: 28231819
[TBL] [Abstract][Full Text] [Related]
28. EGFR mutations in surgically resected fresh specimens from 697 consecutive Chinese patients with non-small cell lung cancer and their relationships with clinical features.
Lai Y; Zhang Z; Li J; Sun D; Zhou Y; Jiang T; Han Y; Huang L; Zhu Y; Li X; Yan X
Int J Mol Sci; 2013 Dec; 14(12):24549-59. PubMed ID: 24351833
[TBL] [Abstract][Full Text] [Related]
29. The different efficacy of gefitinib or erlotinib according to epidermal growth factor receptor exon 19 and exon 21 mutations in Korean non-small cell lung cancer patients.
Sun JM; Won YW; Kim ST; Kim JH; Choi YL; Lee J; Park YH; Ahn JS; Park K; Ahn MJ
J Cancer Res Clin Oncol; 2011 Apr; 137(4):687-94. PubMed ID: 20552223
[TBL] [Abstract][Full Text] [Related]
30. Serial cfDNA assessment of response and resistance to EGFR-TKI for patients with EGFR-L858R mutant lung cancer from a prospective clinical trial.
Zhou Q; Yang JJ; Chen ZH; Zhang XC; Yan HH; Xu CR; Su J; Chen HJ; Tu HY; Zhong WZ; Yang XN; Wu YL
J Hematol Oncol; 2016 Sep; 9(1):86. PubMed ID: 27619632
[TBL] [Abstract][Full Text] [Related]
31. Impact of EGFR-TKI Treatment on the Tumor Immune Microenvironment in
Isomoto K; Haratani K; Hayashi H; Shimizu S; Tomida S; Niwa T; Yokoyama T; Fukuda Y; Chiba Y; Kato R; Tanizaki J; Tanaka K; Takeda M; Ogura T; Ishida T; Ito A; Nakagawa K
Clin Cancer Res; 2020 Apr; 26(8):2037-2046. PubMed ID: 31937613
[TBL] [Abstract][Full Text] [Related]
32. [Relationship between EGFR and KRAS mutations and prognosis in Chinese patients with non-small cell lung cancer: a mutation analysis with real-time polymerase chain reaction using scorpion amplification refractory mutation system].
Gao J; Chen JQ; Zhang L; Liang ZY
Zhonghua Bing Li Xue Za Zhi; 2012 Oct; 41(10):652-6. PubMed ID: 23302304
[TBL] [Abstract][Full Text] [Related]
33. Somatic HLA Class I Loss Is a Widespread Mechanism of Immune Evasion Which Refines the Use of Tumor Mutational Burden as a Biomarker of Checkpoint Inhibitor Response.
Montesion M; Murugesan K; Jin DX; Sharaf R; Sanchez N; Guria A; Minker M; Li G; Fisher V; Sokol ES; Pavlick DC; Moore JA; Braly A; Singal G; Fabrizio D; Comment LA; Rizvi NA; Alexander BM; Frampton GM; Hegde PS; Albacker LA
Cancer Discov; 2021 Feb; 11(2):282-292. PubMed ID: 33127846
[TBL] [Abstract][Full Text] [Related]
34. Characterization of the Immune Landscape of EGFR-Mutant NSCLC Identifies CD73/Adenosine Pathway as a Potential Therapeutic Target.
Le X; Negrao MV; Reuben A; Federico L; Diao L; McGrail D; Nilsson M; Robichaux J; Munoz IG; Patel S; Elamin Y; Fan YH; Lee WC; Parra E; Solis Soto LM; Chen R; Li J; Karpinets T; Khairullah R; Kadara H; Behrens C; Sepesi B; Wang R; Zhu M; Wang L; Vaporciyan A; Roth J; Swisher S; Haymaker C; Zhang J; Wang J; Wong KK; Byers LA; Bernatchez C; Zhang J; Wistuba II; Gibbons DL; Akbay EA; Heymach JV
J Thorac Oncol; 2021 Apr; 16(4):583-600. PubMed ID: 33388477
[TBL] [Abstract][Full Text] [Related]
35. Src mediates cigarette smoke-induced resistance to tyrosine kinase inhibitors in NSCLC cells.
Filosto S; Baston DS; Chung S; Becker CR; Goldkorn T
Mol Cancer Ther; 2013 Aug; 12(8):1579-90. PubMed ID: 23686837
[TBL] [Abstract][Full Text] [Related]
36. Late-differentiated effector neoantigen-specific CD8+ T cells are enriched in peripheral blood of non-small cell lung carcinoma patients responding to atezolizumab treatment.
Fehlings M; Jhunjhunwala S; Kowanetz M; O'Gorman WE; Hegde PS; Sumatoh H; Lee BH; Nardin A; Becht E; Flynn S; Ballinger M; Newell EW; Yadav M
J Immunother Cancer; 2019 Sep; 7(1):249. PubMed ID: 31511069
[TBL] [Abstract][Full Text] [Related]
37. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
38. Efficacy of Icotinib, an EGFR Tyrosine Kinase Inhibitor in Non-Small Cell Lung Cancer Patients with Exon 19 Deletion and Exon 21 L858R: A Retrospective Analysis in China.
Wang Y; Yuan X; Yang M; Shen Z; Chen H; He X; Ma Y; Ding L
Pharmacology; 2021; 106(11-12):658-666. PubMed ID: 34673645
[TBL] [Abstract][Full Text] [Related]
39. Epidermal growth factor receptor double activating mutations involving both exons 19 and 21 exist in Chinese non-small cell lung cancer patients.
Zhang GC; Lin JY; Wang Z; Zhou Q; Xu CR; Zhu JQ; Wang K; Yang XN; Chen G; Yang JJ; Huang YJ; Liao RQ; Wu YL
Clin Oncol (R Coll Radiol); 2007 Sep; 19(7):499-506. PubMed ID: 17537621
[TBL] [Abstract][Full Text] [Related]
40. HLA-corrected tumor mutation burden and homologous recombination deficiency for the prediction of response to PD-(L)1 blockade in advanced non-small-cell lung cancer patients.
Shim JH; Kim HS; Cha H; Kim S; Kim TM; Anagnostou V; Choi YL; Jung HA; Sun JM; Ahn JS; Ahn MJ; Park K; Park WY; Lee SH
Ann Oncol; 2020 Jul; 31(7):902-911. PubMed ID: 32320754
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
